Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality

Metabolic syndrome: SGLT2i prevents diabetic cachexia and prolongs survival Sodium-glucose cotransporter 2 inhibitor (SGLT2i) has a favorable effect on mortality of diabetic subjects, but the mechanism stays unclear. Taichi Sugizaki at Kumamoto University examined SGLT2i effects in severe diabetic o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Taichi Sugizaki, Shunshun Zhu, Ge Guo, Akiko Matsumoto, Jiabin Zhao, Motoyoshi Endo, Haruki Horiguchi, Jun Morinaga, Zhe Tian, Tsuyoshi Kadomatsu, Keishi Miyata, Hiroshi Itoh, Yuichi Oike
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/a2c42276f5e74aac86a47284b4a91626
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2c42276f5e74aac86a47284b4a91626
record_format	dspace
spelling	oai:doaj.org-article:a2c42276f5e74aac86a47284b4a916262021-12-02T14:18:31ZTreatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality10.1038/s41514-017-0012-02056-3973https://doaj.org/article/a2c42276f5e74aac86a47284b4a916262017-09-01T00:00:00Zhttps://doi.org/10.1038/s41514-017-0012-0https://doaj.org/toc/2056-3973Metabolic syndrome: SGLT2i prevents diabetic cachexia and prolongs survival Sodium-glucose cotransporter 2 inhibitor (SGLT2i) has a favorable effect on mortality of diabetic subjects, but the mechanism stays unclear. Taichi Sugizaki at Kumamoto University examined SGLT2i effects in severe diabetic obese mice, and discovered that they showed prolonged survival without pathological weight loss, or cachexia. As with SGLT2i, Insulin also prevented cachexia, improved pancreatic beta cell function, insulin sensitivity and some organ damages. However, what makes SGLT2i important was to suppress cellular aging or vessel inflammation, while insulin accelerated those developments, which may lead to a result that SGLT2i has contributed to prolonged survival more than insulin. SGLT2i demonstrates an association with survival period upon maintaining good condition of pancreatic beta cells and insulin target organs, providing insight into strategies for treatment of severe diabetes.Taichi SugizakiShunshun ZhuGe GuoAkiko MatsumotoJiabin ZhaoMotoyoshi EndoHaruki HoriguchiJun MorinagaZhe TianTsuyoshi KadomatsuKeishi MiyataHiroshi ItohYuichi OikeNature PortfolioarticleGeriatricsRC952-954.6ENnpj Aging and Mechanisms of Disease, Vol 3, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Taichi Sugizaki Shunshun Zhu Ge Guo Akiko Matsumoto Jiabin Zhao Motoyoshi Endo Haruki Horiguchi Jun Morinaga Zhe Tian Tsuyoshi Kadomatsu Keishi Miyata Hiroshi Itoh Yuichi Oike Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
description	Metabolic syndrome: SGLT2i prevents diabetic cachexia and prolongs survival Sodium-glucose cotransporter 2 inhibitor (SGLT2i) has a favorable effect on mortality of diabetic subjects, but the mechanism stays unclear. Taichi Sugizaki at Kumamoto University examined SGLT2i effects in severe diabetic obese mice, and discovered that they showed prolonged survival without pathological weight loss, or cachexia. As with SGLT2i, Insulin also prevented cachexia, improved pancreatic beta cell function, insulin sensitivity and some organ damages. However, what makes SGLT2i important was to suppress cellular aging or vessel inflammation, while insulin accelerated those developments, which may lead to a result that SGLT2i has contributed to prolonged survival more than insulin. SGLT2i demonstrates an association with survival period upon maintaining good condition of pancreatic beta cells and insulin target organs, providing insight into strategies for treatment of severe diabetes.
format	article
author	Taichi Sugizaki Shunshun Zhu Ge Guo Akiko Matsumoto Jiabin Zhao Motoyoshi Endo Haruki Horiguchi Jun Morinaga Zhe Tian Tsuyoshi Kadomatsu Keishi Miyata Hiroshi Itoh Yuichi Oike
author_facet	Taichi Sugizaki Shunshun Zhu Ge Guo Akiko Matsumoto Jiabin Zhao Motoyoshi Endo Haruki Horiguchi Jun Morinaga Zhe Tian Tsuyoshi Kadomatsu Keishi Miyata Hiroshi Itoh Yuichi Oike
author_sort	Taichi Sugizaki
title	Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
title_short	Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
title_full	Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
title_fullStr	Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
title_full_unstemmed	Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
title_sort	treatment of diabetic mice with the sglt2 inhibitor ta-1887 antagonizes diabetic cachexia and decreases mortality
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a2c42276f5e74aac86a47284b4a91626
work_keys_str_mv	AT taichisugizaki treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT shunshunzhu treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT geguo treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT akikomatsumoto treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT jiabinzhao treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT motoyoshiendo treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT harukihoriguchi treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT junmorinaga treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT zhetian treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT tsuyoshikadomatsu treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT keishimiyata treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT hiroshiitoh treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality AT yuichioike treatmentofdiabeticmicewiththesglt2inhibitorta1887antagonizesdiabeticcachexiaanddecreasesmortality
_version_	1718391623557054464

Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality

Ejemplares similares